DrugPatentWatch Database Preview
EPANOVA Drug Profile
or, see our see our flat-rate plans
When do Epanova patents expire, and when can generic versions of Epanova launch?
This drug has eighty-five patent family members in thirty-eight countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this compound. Additional details are available on the omega-3-carboxylic acids profile page.
Summary for EPANOVA
| International Patents: | 85 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 15 |
| Patent Applications: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | EPANOVA at DailyMed |
Synonyms for EPANOVA
| Anti-hypertriglycemic (oral/capsule, hypertriglyceridemia/crohn's disease), Omthera |
| D0G7WY |
| F005100000 |
| Fatty Acids, Omega-3 |
| n-3 Polyunsaturated Fatty Acid |
| n-3 PUFA |
| n-3 PUFAs |
| Omefas |
| Omega-3 Fatty Acids |
| Omega-3 Polyunsaturates |
| Polyunsaturated Fatty Acids (PUFAs) |
| QPEOIOLHJXXJFN-GNGJDXFDSA-N |
US Patents and Regulatory Information for EPANOVA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Pharms | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Astrazeneca Pharms | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Astrazeneca Pharms | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Astrazeneca Pharms | EPANOVA | omega-3-carboxylic acids | CAPSULE;ORAL | 205060-001 | May 5, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Non-Orange Book US Patents for EPANOVA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,729,321 | Autonomous private key recovery | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
or, see our see our flat-rate plans
